As World Aids Day is marked on Sunday 1 December, around 35 million
people across the globe are living with HIV. Whilst it is encouraging to
see that new cases of HIV infections and Aids continue to fall - in
2012, 2.3 million people worldwide became infected with HIV, a 33%
reduction since 2001 - experts believe that starting treatment much
earlier is the key to combatting the spread of infection. To achieve
this, the international private sector is being urged to take the lead
in demonstrating its commitment to combating the fight against HIV/Aids.
"We
know that investment in HIV/Aids prevention and treatment delivers
tangible results," explains Dr Brian Brink, Anglo American's chief
medical officer, vice-chair of the Audit and Ethics Committee of the
Global Fund and a leading authority on the business response to HIV/Aids
and TB.
"The downturn in new infections was largely due to the
increased global investment in the HIV/Aids response from both PEPFAR
(the US President's Emergency Plan for Aids Relief) and the Global Fund
to fight Aids, TB and Malaria."
The Global Fund is an innovative
partnership platform uniting government, civil society and the private
sector to direct increased funding to the poorest countries with the
least access to care, support and treatment.
"I want to urge all
major British companies with a global presence to join forces and made
an investment in the Global Fund to help end HIV/Aids across the world,"
says Brink. "We know it can be done – we are starting to see results –
but we need more support to reach our end goal of zero new infections."
Brink
supports the UNAIDS proposition that scaling up HIV treatment in
accordance with the newly announced World Health Organisation (WHO)
guidelines could prevent up to 65 million deaths globally by 2050.
"The
biggest investment has been in treatment, and one of the most
fundamental changes we have seen in recent years is that HIV itself is
being treated rather than waiting for people to develop Aids. HIV
treatment now is simpler and less toxic, so starting treatment even
earlier could make a significant difference. Studies have conclusively
shown that earlier treatment leads to a dramatic reduction in the number
of new HIV infections, the primary reason being that HIV infected
people receiving treatment are very unlikely to pass the infection on."
The
initiation of treatment is based on the CD4 lymphocyte count – the best
indicator of the state of the immune system in an HIV infected person.
A normal CD4 count falls in the range 600 – 1500 cells per microlitre,
but with HIV infection it progressively drops below this range; a CD4
cell count below 200 is taken to define the onset of Aids in an HIV
infected person. Under the new WHO guidelines, antiretroviral treatment
should commence when the CD4 count drops below 500. Many believe that
treatment should start as soon as possible – when a patient has been
properly counselled and is prepared to commit to treatment – regardless
of CD4 count.
Brink cites the results of the 'HPTN052' trial
released on 12 May 2011, which evaluated the risk of HIV transmission in
discordant couples (where only person in the couple is infected with
HIV). Half of the study group received HIV treatment and used condoms,
whereas the other half only used condoms. After two years, new
infections in treated couples was 96% lower than in untreated couples.
The trial therefore showed that if an HIV positive person adheres to an
effective antiretroviral therapy regimen, the risk of transmitting the
virus to their uninfected sexual partner can be reduced by 96%.
Earlier
treatment, which could prevent up to 65 million deaths globally by
2050, requires scaling up of treatment to 23 million on treatment by
2025. This will need a huge commitment and investment from both the
international private sector and a coordinated funding approach.
No hay comentarios:
Publicar un comentario